Statins are the basis of lipid-lowering therapy. When using the most potent atorvastatin or rosuvastatin, LDL-C can be reduced by up to 60%. In clinical practice, not all patients achieve the target LDL cholesterol, especially those with familial hypercholesterolaemia, statin intolerance, or those at very high cardiovascular risk. These patients should be considered for combination treatment. The new PCS K9 drug inhibitors are a very promising form of lipid-lowering therapy. In patients with atherogenic dyslipidaemia with TG > 200 mg/dl (2.3 mmol/l) despite statin treatment, fenofibrate may be considered in combination with statins.